How to Validate Feasibility Questionnaire Responses in Clinical Trials

The Importance of Validating Feasibility Data

Feasibility questionnaires play a critical role in determining whether a clinical trial site is suitable for participation. However, these tools are only as good as the accuracy of the responses they generate. Self-reported data—if unverified—can lead to unrealistic enrollment projections, infrastructure mismatches, and serious regulatory non-compliance during inspections.

According to ICH E6(R2) and GCP guidelines, sponsors must implement a risk-based approach to trial planning, which includes verification of feasibility assessments. The FDA, EMA, and other global authorities expect documented evidence supporting site claims about patient access, PI experience, prior performance, and infrastructure readiness.

This article provides a step-by-step guide on how to validate feasibility questionnaire responses using cross-verification methods, documentation, risk scoring, and regulatory best practices. Real-world case examples and recommended tools are included.

What Needs Validation in Feasibility Responses?

The following aspects of a typical feasibility questionnaire require validation:

• Patient population estimates
• Investigator clinical trial experience
• Site infrastructure and equipment availability
• Ethics committee and regulatory approval timelines
• Past performance metrics (e.g., enrollment rates, deviation frequency)

These elements are often misreported due to over-optimism, human error, or poor recordkeeping. Therefore, a structured validation process is essential.

Methods for Cross-Validation of Responses

Multiple techniques are used to cross-check the authenticity of feasibility responses:

1. Use of Internal Databases (CTMS, EDC)

Sponsors can retrieve historical trial performance from CTMS to compare with the current feasibility response. For instance, if a site claims it can enroll 60 patients in 6 months, but prior CTMS data shows 20 patients in 12 months for a similar study, this claim warrants further review.

2. Reference to External Registries

Public registries like ISRCTN and ClinicalTrials.gov allow sponsors to validate investigator participation in previous studies and enrollment timelines. Sponsors can match PI names, protocol IDs, and trial dates.

3. Request for Supporting Documents

Sites should provide de-identified hospital records, patient logs, or EHR data to support population claims. For infrastructure, calibration certificates, equipment photos, and maintenance logs should be reviewed.

4. Follow-Up Interviews or Site Televisits

If discrepancies arise, schedule virtual or onsite meetings with the PI or study coordinator to clarify inconsistencies and gather more accurate estimates.

Feasibility Response Verification Table Example

Red Flags That Indicate Validation Is Required

During feasibility review, the following red flags should trigger further scrutiny:

• Patient recruitment claims 2–3x higher than historical benchmarks
• Incomplete PI CV or GCP certification over 3 years old
• Missing documentation for critical equipment (e.g., -80°C freezers, ECG machines)
• Overly short startup timelines without justification
• Sites with previous high deviation rates claiming full protocol compliance

Each red flag should be documented, followed up, and closed before site activation.

Scoring and Risk Categorization of Responses

Validation can be combined with feasibility scoring models to assign a risk category to each site:

Sites categorized as high risk may require additional support or may be excluded from study participation, depending on trial timelines and resource constraints.

Audit Trail and Documentation Requirements

All validation steps must be auditable and retained in the Trial Master File (TMF) or eTMF. Essential records include:

• Annotated questionnaires with reviewer comments
• Emails or notes from follow-up discussions
• Screenshots or documents verifying responses
• Final approval or decision logs by the feasibility committee

This ensures compliance with FDA 21 CFR Part 11 and EMA inspection expectations. Sponsors may also use feasibility-specific document templates for review and version control.

Common Pitfalls in the Validation Process

• Relying solely on site self-assessment without supporting evidence
• Not checking for updated documents like GCP certificates and calibration logs
• Skipping validation due to tight startup timelines
• No SOP or standardized form for feasibility review

To avoid these issues, sponsors should maintain a dedicated Feasibility Review SOP that outlines timelines, reviewer responsibilities, documentation standards, and escalation criteria.

Tools to Support Feasibility Response Validation

• CTMS: For prior site performance records
• eTMF: For document version control and audit trail
• Feasibility Platforms: Veeva Study Startup, Clario, or TrialHub
• Registry Databases: ISRCTN, ClinicalTrials.gov, EU Trials Register
• Dashboards: Power BI or Tableau for response scoring and risk tracking

Conclusion

Validating feasibility questionnaire responses is a critical part of risk-based site selection and trial planning. Relying on unverified data can lead to poor site performance, regulatory findings, and budget overruns. By implementing structured validation workflows, cross-checking with internal and public databases, documenting all review activities, and integrating risk scoring, sponsors and CROs can ensure high data integrity and regulatory compliance. In today’s complex trial landscape, validated feasibility is not just best practice—it’s a regulatory necessity.

Essential Questions for Designing an Effective Feasibility Questionnaire

Understanding the Role of Feasibility Questionnaires

Before selecting sites and investigators, sponsors and CROs must carefully evaluate a site’s ability to successfully execute a clinical trial. A feasibility questionnaire is one of the most important tools for this assessment. These documents collect structured information about a site’s resources, patient pool, regulatory experience, and infrastructure readiness. Regulatory agencies such as the FDA, EMA, and national authorities expect sponsors to document feasibility efforts as part of Good Clinical Practice (GCP) compliance. Without a robust feasibility process, sponsors risk delays, under-enrollment, and inspection findings during trial audits.

Feasibility questionnaires typically cover domains such as:

• Patient recruitment and retention potential
• Principal Investigator (PI) and sub-investigator experience
• Site infrastructure, including equipment and labs
• Previous performance in similar therapeutic areas
• Local regulatory and ethics committee processes

For example, in oncology studies, questionnaires often probe whether the site has access to pathology labs capable of immunohistochemistry testing, or whether genetic testing partnerships exist. In infectious disease studies, questions may focus on availability of biosafety level facilities. Thus, while core domains remain consistent, therapeutic area–specific tailoring is essential.

Critical Patient-Related Questions

Patient recruitment is one of the most common barriers to timely trial completion. Regulators, including the European Medicines Agency (EMA), emphasize that feasibility assessments should be realistic and data-driven. A questionnaire must therefore ask targeted questions about patient populations. Examples include:

Incorporating epidemiological data strengthens these questions. For example, if a site estimates 300 eligible patients annually but national disease burden data suggests fewer than 50 cases in the region, this discrepancy raises concerns about overestimation. Sponsors should cross-check questionnaire responses with external databases such as ClinicalTrials.gov to validate feasibility claims against trial recruitment histories.

Questions on Investigator and Staff Experience

A site’s human resources are equally critical. Regulators often highlight inadequate investigator oversight as a frequent finding in inspections. Questionnaires should evaluate whether the PI and supporting staff have the necessary experience. Key questions include:

• How many clinical trials has the PI conducted in the past five years, and in which therapeutic areas?
• Has the PI received any regulatory inspection findings related to GCP?
• What is the average turnover rate of study coordinators and research nurses?
• What GCP training and certification do staff currently hold?

For example, a PI with ten oncology trials completed but with multiple FDA Form 483 citations may be a higher risk compared to a less experienced PI with a clean regulatory record. Feasibility questionnaires should capture such nuances.

Infrastructure and Technology Questions

Infrastructure capability directly influences trial quality. For complex trials requiring bioanalytical testing, imaging, or cold-chain management, questionnaires must go beyond basic facilities inquiries. Sample questions include:

• Does the site have validated -80°C freezers with continuous temperature monitoring?
• Are backup power systems in place to safeguard sample integrity?
• Is the site equipped with validated software for electronic data capture (EDC)?
• Are laboratory instruments calibrated according to international standards (e.g., ISO 15189)?

Some questionnaires include sample validation parameters such as:

These details help sponsors differentiate between sites that claim readiness and those that are genuinely prepared for trial operations.

Regulatory and Ethics Questions

Finally, feasibility questionnaires must assess local regulatory and ethics environments. Delays in IRB/EC approvals are a common reason for missed trial timelines. Essential questions include:

• What is the average IRB/EC review timeline for clinical trials at your institution?
• Do you have prior experience submitting to regulatory authorities such as FDA, EMA, CDSCO, or PMDA?
• Are there institutional policies restricting enrollment of vulnerable populations?

For example, if a site reports an average of 45 days for ethics approvals, sponsors can plan activation timelines accordingly. Sites with extended timelines (e.g., >90 days) may not be suitable for fast-track studies.

Transition to Next Considerations

The above domains—patient recruitment, investigator experience, infrastructure, and regulatory landscape—form the backbone of feasibility questionnaires. However, sponsors must also evaluate validation of responses, data reliability, and strategies to prevent overpromising. These aspects will be explored in Part 2, with focus on case studies, pitfalls, and best practices for robust feasibility planning.

Validating Feasibility Questionnaire Responses

Feasibility questionnaires are only useful if responses are accurate. Regulators and sponsors increasingly emphasize data verification as part of trial oversight. Sponsors must apply validation strategies to ensure that sites are not inflating capabilities or patient pools to secure trial participation.

One approach is to cross-verify patient pool estimates with hospital records, referral databases, or national disease registries. For example, if a site reports 500 annual cases of Type 2 diabetes, but regional public health data suggests only 300 cases, the sponsor should investigate. Similarly, sponsors should request anonymized patient counts or ICD-10 code reports to substantiate claims.

Case Study: Inflated Patient Recruitment Claims

A multinational sponsor faced delays in an oncology trial when three sites overestimated recruitment potential. While questionnaires projected 50 patients per site annually, actual enrollment was less than 10. Upon review, it was found that sites included patients outside inclusion criteria. This case underscores the importance of rigorous validation, including review of electronic health records (EHRs) and prior recruitment histories from registries such as ISRCTN Registry.

Common Pitfalls in Questionnaire Design

Despite best intentions, poorly designed questionnaires often result in incomplete or misleading data. Common pitfalls include:

• Overly generic questions that do not capture therapeutic-specific nuances
• Yes/No questions without quantitative context (e.g., “Do you have lab facilities?” instead of “How many calibrated centrifuges are available?”)
• Failure to include data validation fields or request supporting documentation
• Excessive questionnaire length leading to incomplete responses

To avoid these issues, sponsors should pilot-test questionnaires with selected sites and adjust based on feedback. Regulatory authorities also recommend focusing on essential questions that directly impact trial feasibility, rather than exhaustive lists that burden sites unnecessarily.

Best Practices for Effective Questionnaires

Effective feasibility questionnaires balance comprehensiveness with clarity. Best practices include:

• Tailoring questionnaires by therapeutic area (oncology, cardiology, infectious disease)
• Using a mix of quantitative and qualitative questions
• Integrating electronic platforms to streamline completion and analysis
• Embedding mandatory data validation checks (e.g., requiring supporting documentation uploads)

Some sponsors now deploy digital feasibility tools integrated with Clinical Trial Management Systems (CTMS). These allow automated scoring, comparison across sites, and identification of red flags such as inconsistent patient data. For example, an AI-enabled feasibility tool might score sites based on patient pool adequacy, infrastructure readiness, and regulatory history, generating a composite feasibility index for decision-making.

Sample Feasibility Scoring Framework

This weighted approach ensures objective decision-making while allowing customization for specific trial needs. For instance, in rare disease studies with small populations, patient recruitment weight might increase to 60%.

Conclusion

Feasibility questionnaires are a cornerstone of site selection and clinical trial planning. By including targeted questions on patients, investigators, infrastructure, and regulatory environment—and by validating responses through data cross-checks—sponsors can mitigate risks of underperformance and regulatory non-compliance. Effective design not only accelerates trial start-up but also strengthens inspection readiness by demonstrating a structured feasibility process.